Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW

Rituximab Injection.

Rituximab injection, indications: This product is suitable for the treatment of relapsed or resistant follicular central lymphoma (B-cell non-Hodgkin’s lymphoma of International Working Classification B, C and D subtypes). Previously untreated CD20-positive stage III-IV follicular non-Hodgkin’s lymphoma patients should be treated with standard CVP chemotherapy (cyclophosphamide, vincristine and prednisone) for 8 cycles. CD20-positive diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) should be treated with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for 8 cycles.

Share: